Tenosynovial giant cell tumor (TGCT) is a group of rare tumors. They are usually benign (not cancer) and tend to occur in people between 25 to 50 years old. The tumors affect areas of the joints ...

Results from a phase 1 trial showed the independently reviewed best overall objective response rate was 71% in emactuzumab-treated patients. The Food and Drug Administration (FDA) has granted Fast ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition ...

Emactuzumab demonstrated a 71% objective response rate, rapid tumor reduction, and manageable side effects in early trials. Emactuzumab has received fast track designation from the U.S. FDA for ...